Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Jun

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer

First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors

CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC

Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer